Novo Nordisk shares rose after the Danish obesity-drug maker's first-quarter earnings topped Wall Street expectations. As widely anticipated, the drug maker reduced its growth forecast to reflect the ...

Novo Nordisk, which also makes Wegovy, fell victim to 'compounding' - a practice in the US that allows pharmacies to produce ...

Bio-Techne surpasses profit expectations with significant growth in its research products, leading to the announcement of a ...

Collaboration Revenue: There was $2.6 million of collaboration revenue for the three months ended March 31, 2025, as compared to no collaboration revenue for the three months ended March 31, 2024. The ...

Walt Disney (NYSE: DIS ) stock more than 10% after the entertainment giant reported fiscal second-quarter earnings that beat ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; Novo’s has fallen by as much (see chart 2). Lilly’s edge rests on a more ...

A man is suing the manufacturers of Ozempic, alleging the diabetes drug caused him to go blind. The medication, containing semaglutide, works by regulating blood sugar and suppressing hunger. While ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.

Shares of Novo Nordisk climbed nearly 7% on Wednesday after the company said sales of its obesity drug Wegovy are expected to ...

Novo Nordisk reports its results in Danish kroner (DKK) rather than U.S. dollars. Sales grew 19% year over year to 78.1 ...